Long-term oral antiarrhythmic therapy with aprindine (AC 1802).
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D000814:Aniline Compounds; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage*; D001281:Atrial Fibrillation / Q000188:drug therapy; D001282:Atrial Flutter / Q000188:drug therapy; D005117:Cardiac Complexes, Premature / Q000188:drug therapy; D004048:Diethylamines; D005260:Female; D006325:Heart Atria; D006352:Heart Ventricles; D006801:Humans; D007189:Indans / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D007192:Indenes / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D007319:Sleep Initiation and Maintenance Disorders / Q000139:chemically induced; D013610:Tachycardia / Q000188:drug therapy; D013997:Time Factors; D014202:Tremor / Q000139:chemically induced; D014717:Vertigo / Q000139:chemically induced
D000814:Aniline Compounds; D000889:Anti-Arrhythmia Agents; D004048:Diethylamines; D007189:Indans; D007192:Indenes